Daily Medication Pearl: Maralixibat (Livmarli) for Cholestatic Pruritus

Article

Maralixibat decreases the reabsorption of bile acids from the terminal ileum for the treatment of cholestatic pruritus in patients with Alagille syndrome.

Clinical Pearl of the Day: Maralixibat (Livmarli)

Maralixibat is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Insight:

  • Dosage: The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day. Starting dose is 190 mcg/kg orally once daily and should be increased to 380 mcg/kg once daily after 1 week, as tolerated.
  • Dosing: Oral solution 9.5 mg of maralixibat per mL.
  • Adverse events: Include diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
  • Mechanism of action: Maralixibat decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
  • Manufacturer: Mirum

Sources:

Approval [Rx ONLY] (mirumpharma.com)

livmarli - Google Search

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.